Foghorn Therapeutics Inc Ordinary Shares FHTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FHTX is a good fit for your portfolio.
News
-
Thinking about buying stock in Foghorn Therapeutics, Oscar Health, Eli Lilly And Co, Palo Alto Networks, or CN ENERGY GROUP?
-
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product
-
Foghorn Therapeutics Shares Rally Premarket as FDA Lifts Clinical Hold
-
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial
Trading Information
- Previous Close Price
- $5.16
- Day Range
- $5.15–5.62
- 52-Week Range
- $2.70–9.97
- Bid/Ask
- $5.14 / $5.78
- Market Cap
- $221.77 Mil
- Volume/Avg
- 111,333 / 160,063
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.40
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 116
- Website
- https://www.foghorntx.com
Comparables
Valuation
|
Metric
|
FHTX
|
VOR
|
RVMD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.78 | 3.21 |
Price/Sales | 6.40 | — | 347.76 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FHTX
|
VOR
|
RVMD
|
|---|---|---|---|
Quick Ratio | 4.01 | 8.81 | 12.89 |
Current Ratio | 4.11 | 9.04 | 13.06 |
Interest Coverage | — | — | −1,607.49 |
Quick Ratio
FHTX
VOR
RVMD
Profitability
|
Metric
|
FHTX
|
VOR
|
RVMD
|
|---|---|---|---|
Return on Assets (Normalized) | −24.94% | −41.83% | −31.22% |
Return on Equity (Normalized) | — | −51.69% | −35.83% |
Return on Invested Capital (Normalized) | −1,425.88% | −47.03% | −37.83% |
Return on Assets
FHTX
VOR
RVMD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Smrqxkct | Bsbgf | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wwvsfbzpp | Btftcff | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nxygzmlp | Fjjnp | $99.5 Bil | |
MRNA
| Moderna Inc | Qjkjbpsf | Fbw | $38.8 Bil | |
ARGX
| argenx SE ADR | Hvprzckzs | Ynnb | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Lfjvlbhp | Pmhs | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jynfplld | Smdtddh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rxkcnrc | Hdvywcb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gpbfxjprj | Dkqpb | $12.5 Bil | |
INCY
| Incyte Corp | Xybvwgkx | Jsdywmw | $11.6 Bil |